ZL-1102 Gel for Psoriasis

Phase 2

Recruiting

Research Sponsored by Zai Lab (Hong Kong), Ltd.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

Positive for any of the following tests at screening: Human immunodeficiency virus (HIV): HIV antibody, Hepatitis B virus (HBV): hepatitis B surface antigen (HBsAg)/hepatitis B core antibody (HBcAb)/HBV DNA, Hepatitis C virus (HCV): HCV RNA, Patients with active tuberculosis (TB) or untreated latent TB per local guidelines, History of and/or concurrent condition of inflammatory bowel disease (IBD) (ulcerative colitis and Crohn's disease), or signs/symptoms of IBD at screening that, in the opinion of the Investigator, pose an unacceptable risk to the patient if participating in the study, History of and/or concurrent condition of serious hypersensitivity (anaphylactic shock or anaphylactoid reaction) to IL-17 antibodies and any human or humanized biological agents, Patients who have a history of malignancy unless deemed cured by adequate treatment with no evidence of recurrence for ≥ 3 years before the initiation of study treatment, Patients with a history of chronic alcohol or drug abuse within 6 months of the initiation of study treatment, as determined by the Investigator, Prior exposure to ZL-1102, Patients who have received a live vaccine within 6 weeks prior to dosing on Day 1, Females who are pregnant, wishing to become pregnant during the study, or are breastfeeding

Other types of psoriasis dominant other than plaque psoriasis (e.g., pustular, erythrodermic, guttate, palmar, plantar, scalp or nail disease) or the lesion is not eligible for topical treatment only

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 20 weeks

Summary

This trial will test different doses of a topical gel called ZL-1102 to see how well it works and how safe it is for treating chronic plaque psoriasis.

Who is the study for?

This trial is for individuals with chronic plaque psoriasis. Participants should have a stable disease state and be willing to apply the study gel as directed throughout the trial period. Specific details about who can join are not provided, but typically participants must meet certain health criteria.

What is being tested?

The study is testing ZL-1102, a topical gel designed to treat plaque psoriasis by targeting IL-17A, which is involved in inflammation. Patients will be randomly assigned to receive different doses of ZL-1102 or a placebo without knowing which one they're getting.

What are the potential side effects?

Potential side effects are not listed, but since ZL-1102 targets the immune system, it may cause skin reactions at the application site or affect immune responses. The exact side effects will be monitored and recorded during the trial.